Dan’s research focuses on understanding the mechanisms of pathogenesis, and identifying prognostic biomarkers of the severe cutaneous adverse drug reactions (ADRS) Stevens-Johnson syndrome and toxic epidermal necrolysis. He has a particular interest in the development of novel in vitro models utilising induced pluripotent stem cells derived from ADR patient PBMCs for advancing our understanding of what predisposes certain individuals to drug-induced skin blistering reactions. Furthermore he has a long held interest and expertise in the study of pharmacogenomics of adverse drug reactions spanning a wide range of therapeutics and clinical disciplines.
Drug-induced mitochondrial toxicity is a major pathway in adverse drug-reactions across many organs. However, there is little evidence of how this pathway translates to the clinical onset of toxicity in certain individuals. Therefore the research of the Bioenergetic Group, led by Amy, is focused upon elucidating the fundamental mechanisms of drug-induced mitochondrial dysfunction and translating this knowledge to define the molecular and genetic factors underlying individual susceptibility to mitotoxicants. The group currently focusses on liver and muscle toxicity and work with a range of in vitro models including transmitochondrial cybrids, primary hepatocytes, HepaRG cells and myobundles.
Having worked on understanding fundamental mechanisms of apoptosis for many years, some of Gerry's current work concentrates on utilising this knowledge in improving current cancer treatments using chemotherapy. In research funded by NWCR, his group is currently establishing a method known as BH3 profiling. This method can then be used to ascertain whether different individuals will be sensitive or resistant to different chemotherapeutic agents. Other aspects of his current research involve understanding both apoptotic and non-apoptotic roles of BCL-2 family proteins and the further understanding the significance of a novel endoplasmic reticulum stress response recently identified in his laboratory.
Ian’s research focuses on understanding the mechanisms by which cells sense and adapt to chemical entities (particularly therapeutic drugs) and how this influences the balance between efficacy and toxicity. A current focus is the NRF2 stress response pathway, which controls the expression of a range of cytoprotective genes in mammalian cells. Ian’s research focuses on better understanding the types of stress that NRF2 protects against, how it does this, and whether measuring this response can help us to predict the toxic side effects associated with existing and new medicines. He is also interested in the potential of NRF2 as a new therapeutic target in several diseases.
The focus of David’s research group is on blood-brain barrier transporters. This research lies at the interface of drug transporters, blood-brain barrier (BBB) biology and molecular properties that determine the mechanism of transporter action. During his career, David has developed skills in biochemistry, molecular cell biology, drug transporter pharmacology and in vitro models of the BBB. The BBB is considered a significant bottleneck to the development of new CNS treatments with the additional challenge of disease specific effects. David’s recent novel findings include identifying lamotrigine as a substrate for OCT1, determining that ABT-263 is a P-glycoprotein substrate, characterising gabapentin as a LAT1 substrate and defining LAT1s interaction with cholesterol.
Carrie’s research interests are focused on the regulation of gastrointestinal architecture and the maintenance of gut homeostasis with a focus on the intestinal epithelium. Her lab aims to target the processes and mechanisms responsible for this breakdown of intestinal barrier function, epithelial cell destruction and inflammation in order to develop novel therapeutic approaches. They have recently identified the NF-κB2 transcription factor as an important regulator of intestinal epithelial damage in murine in vivo models and in intestinal organoid culture, and are currently developing novel methods to modulate the NF-κB2 signalling pathway to prevent injury to the intestinal epithelium.
Andrew is Professor of Statistical Genetics in the Department of Biostatistics. His research focusses on the development, evaluation and application of methodology for the analysis of genome-wide association and sequencing studies. Key themes of his research include the aggregation of genetic data from diverse populations through trans-ethnic meta-analysis and fine-mapping of complex trait loci through integration with epigenomic and transcriptomic resources to identify causal genes underlying common human disease. He has co-led international collaborative efforts to enhance understanding of a wide range of complex traits, including type 2 diabetes, obesity and kidney function. His team have also focussed on the development of software tools to enable efficient analysis of “time-to-event” outcomes in pharmacogenetic studies of adverse drug reactions and treatment efficacy.
The main theme of Kevin’s research has been to investigate the role of drug disposition in drug response, both pharmacological and toxicological, which led to him founding the MRC Centre for Drug Safety Science in 2009. His research interests span clinical pharmacology, basic pharmacology/toxicology and medicinal chemistry. A major focus of his present work is to investigate clinical, cellular, molecular and chemical mechanisms of adverse drug reactions in man in an integrated fashion, with the long-term goal to develop a rational approach to their prediction and prevention. Adverse drug reactions are a major complication of drug therapy which cause a great deal of patient morbidity and may also result in mortality. Drug toxicity is now considered a major cause of chemical toxicity in man. We have chosen to focus primarily on the fundamental mechanisms involved in those adverse drug reactions which occur in man but are not predictable from present preclinical evaluation.
Professor Sir Munir Pirmohamed is currently David Weatherall Chair in Medicine at the University of Liverpool, and a Consultant Physician at the Royal Liverpool University Hospital. He is Director of the MRC Centre for Drug Safety Sciences, and Director of the Wolfson Centre for Personalised Medicine. He is also an inaugural NIHR Senior Investigator, and Fellow of the Academy of Medical Sciences in the UK. He has authored over 450 peer-reviewed publications, and has an H-index of 92 (Google Scholar). His research focuses on genomic and non-genomic technologies that can be developed and used to progress the field of personalized medicine in an evidence-based, cost-effective and equitable manner. Given his background in clinical pharmacology, most of his research focuses on the use of medicines with the aim of improving their efficacy and minimizing their toxicity, thereby optimizing their harm-benefit ratio.
Cells in virtually all tissues are in contact with organized complexes of structural molecules collectively called the extracellular matrix (ECM). ECM induces a variety of signals that regulate the behavior of cells. As a consequence, tissues or organs keep their normal architecture and homeostasis. Aberrations in signal transduction from the ECM cause chronic degenerative and fibrotic disorders, and cancer progression. The focus of our research group is how drugs affect extracellular matrix (ECM) architecture and how dysregulation of cell-ECM interactions by drugs causes chronic fibrotic disorders and cancer. We utilize extensive mouse genetic approaches, including conditional knockout technology.
Parveen's research focuses on cardiac and liver disease with a specialised interest into drug induced toxicity. The long term aim is to gain a greater understanding of the cellular mechanisms that result in disease, emphasising on key mechanisms and pathways of disease in order to identify clinically relevant therapeutic targets and early detection biomarkers. Parveen's team have a specialised focus on membrane protein physiology, cellular toxicity and the development of 3D cell culture models that emulate more in vivo like structures. For these experiments they apply conventional cell biology and biochemical techniques together with immunofluorescence as well as advanced proteomics and bioinformatics.
Shankar's laboratory is interested in exploring the potential use of small mall inhibitors of the BCL-2 family, also known as BH3 mimetics, in cancer therapy. They study this by assessing – (a) the effectiveness of BH3 mimetics as single agents or in combination with existing therapy in haematological malignancies and cancers of the head and neck as well as pancreas, (b) the role of metabolism in BH3 mimetic-mediated apoptosis, and how that can be exploited in a therapeutic context, and (c) the cellular and molecular mechanisms of BH3 mimetic-mediated apoptosis.
Immune checkpoint inhibitors are medicines that are used in the treatment of cancer to help the body’s own immune system attack the cancer cells. They have been shown to be highly effective but are associated with autoimmune reactions, such as skin rash, which can cause distress to the patient and prevent further courses of treatment being administered. Vincent’s research is focused on understanding the mechanisms of cutaneous toxicity, using modern laboratory techniques such as CyTOF and tissue samples from patients, so that we can avoid these reactions in future drugs and develop treatments for the autoimmune reactions.